MetaVia says it has secured a sweeping global intellectual property portfolio for its experimental metabolic disease drug vanoglipel (DA-1241), reinforcing the company’s push to advance the oral therapy across multiple liver and metabolic conditions.

 

The clinical-stage biotechnology company announced that its patent estate now includes 48 granted and pending patents spanning three patent families across the United States, Europe, Japan, China and other international markets. The protections extend through at least 2035, with the potential for further extensions.

 

The portfolio, exclusively licensed from Dong-A ST Co, covers the vanoglipel compound itself, its manufacturing methods and its potential use in treating a range of serious cardiometabolic and liver diseases. Those protections also include pharmaceutical compositions targeting disorders linked to metabolic dysfunction, such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes.

 

The company’s candidate, vanoglipel, is an orally available G-protein-coupled receptor 119 (GPR119) agonist, a class of drugs designed to help regulate metabolic processes tied to glucose and liver health.

 

"Maintaining and expanding a strong intellectual property position is a core element of our strategy to maximize the long-term value potential of vanoglipel," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. 

 

"These patents reflect the broad therapeutic opportunity for DA-1241 across liver and metabolic diseases and reinforce our commitment to advancing innovative oral treatments for patients who currently have limited options."